Göbel H, Lindner V, Pfaffenrath V, Ribbat M, Heinze A, Stolze H
Neurologisch-verhaltensmedizinische Schmerzklinik Kiel in Kooperation mit dem Klinikum, Christian-Albrechts-Universität Kiel.
Nervenarzt. 1998 Apr;69(4):320-9. doi: 10.1007/s001150050277.
The aim of the open prospective study was to investigate the efficacy, safety and tolerability of subcutaneous sumatriptan in the acute treatment of cluster headache. Self-treatment with 6 mg sumatriptan subcutaneously was monitored over a period up to 1 year. Headache parameters were documented by the patients with a headache diary. A total of 2031 attacks in 52 patients were investigated. Treatment with sumatriptan was effective in 88% of the attacks and 57% of the patients were pain-free within 15 min after injection; 42% of the patients became painfree within 15 min after at least 90% of their attacks. During long-time treatment the efficacy remained unchanged. Of the patients 10% withdrew from the study due to lack of efficacy or adverse events. In total, 62% of the patients reported adverse events, which were serious in 3.8% of the cases. Subcutaneous self-treatment of cluster headache is both highly effective and well tolerated.
这项开放性前瞻性研究的目的是调查皮下注射舒马曲坦治疗丛集性头痛急性发作的疗效、安全性和耐受性。对皮下注射6毫克舒马曲坦的自我治疗进行了长达1年的监测。患者通过头痛日记记录头痛参数。共对52例患者的2031次发作进行了研究。舒马曲坦治疗在88%的发作中有效，57%的患者在注射后15分钟内疼痛缓解；42%的患者在至少90%的发作后15分钟内疼痛缓解。在长期治疗期间，疗效保持不变。10%的患者因缺乏疗效或不良事件退出研究。总体而言，62%的患者报告了不良事件，其中3.8%为严重不良事件。皮下自我治疗丛集性头痛既高效又耐受性良好。
